The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer

Question: In adult patients with advanced or metastatic non-small-cell lung cancer (NSCLC) that has become resistant to platinum-based combination chemotherapy, is there a role for single-agent docetaxel as a second-line therapy? Perspectives: Evidence was selected and reviewed by five members of the Lung Cancer Disease Site Group (DSG) of the Cancer Care Ontario Practice Guidelines Initiative and by a methodologist. The present practice …